A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
2期
已完成
NCT04699630
| 适应症 | Metastatic Breast Cancer, Locally Advanced Breast Cancer |
|---|
| 分期 | 2期 |
|---|
| 申办方 | SCRI Development Innovations, LLC |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 121 人 |
|---|
| 干预（药物） | U3-1402 |
|---|
| 开始日期 | 2021年5月3日 |
|---|
| 完成日期 | 2025年4月9日 |
|---|
| 结果公布日 | 2026年5月7日 |
|---|
摘要
This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast cancer (MBC).
Overall Response Rate (ORR) in Participants With HER2-negative MBC (Part A and Part B)
Assessed every 6 weeks for the first 6 months then every 9 weeks thereafter until disease progression or death or study discontinuation, up to 45 months. · percentage of participants
| Part A | 35 percentage of participants |
|---|
| Part B | 5 percentage of participants |
|---|
Progression-Free Survival at 6 Months (PFS-6) in Participants With HER2-negative MBC (Part A and Part B)
Assessed every 6 weeks for the first 6 months then every 9 weeks thereafter until disease progression or death or study discontinuation, up to 45 months. · percentage of participants
| Part A | 43.3 percentage of participants |
|---|
| Part B | 10.0 percentage of participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。